{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T22:42:50Z","timestamp":1758148970721,"version":"3.44.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":134,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.remnie.2025.500128","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T15:31:40Z","timestamp":1743003100000},"page":"500128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["State of the art and future perspectives of new radionuclides in Nuclear Medicine. Part II"],"prefix":"10.1016","volume":"44","author":[{"given":"L.","family":"Sancho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Roteta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"de Arcocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Quincoces","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2025.500128_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnume.2024.1472500","article-title":"Terbium sisters: current development status and upscaling opportunities","volume":"4","author":"Moiseeva","year":"2024","journal-title":"Front Nucl Med."},{"key":"10.1016\/j.remnie.2025.500128_bib0010","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccr.2018.12.005","article-title":"Radiotheranostics with radiolanthanides: design, development strategies, and medical applications","volume":"383","author":"Mishiro","year":"2019","journal-title":"Coord Chem Rev."},{"key":"10.1016\/j.remnie.2025.500128_bib0015","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.remnie.2025.500128_bib0020","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1134\/S1066362222020011","article-title":"Terbium isotopes in nuclear medicine: production, recovery, and application","volume":"64","author":"Kazakov","year":"2022","journal-title":"Radiochemistry."},{"key":"10.1016\/j.remnie.2025.500128_bib0025","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00259-003-1413-9","article-title":"Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab","volume":"31","author":"Beyer","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500128_bib0030","first-page":"1383","article-title":"Preclinical investigation of [149 Tb] Tb-DOTATATE and [149 Tb] Tb-DOTA- LM3 for tumor-targeted alpha therapy","volume":"52","author":"Katrina","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500128_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-024-53610-2","article-title":"Terbium-149 production: a focus on yield and quality improvement towards preclinical application","volume":"14","author":"Favaretto","year":"2024","journal-title":"Sci Rep."},{"key":"10.1016\/j.remnie.2025.500128_bib0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-016-0189-4","article-title":"Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging","volume":"6","author":"M\u00fcller","year":"2016","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.remnie.2025.500128_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-019-0538-1","article-title":"Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET\/CT imaging of prostate cancer","volume":"9","author":"M\u00fcller","year":"2019","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.remnie.2025.500128_bib0050","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-019-0524-7","article-title":"Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice","volume":"9","author":"Cicone","year":"2019","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.remnie.2025.500128_bib0055","doi-asserted-by":"crossref","first-page":"14638","DOI":"10.1039\/C7DT01936J","article-title":"Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET\/CT with 152Tb-DOTATOC","volume":"46","author":"Baum","year":"2017","journal-title":"Dalt Trans."},{"key":"10.1016\/j.remnie.2025.500128_bib0060","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.nucmedbio.2011.02.007","article-title":"The low-energy \u03b2- and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy","volume":"38","author":"Lehenberger","year":"2011","journal-title":"Nucl Med Biol."},{"key":"10.1016\/j.remnie.2025.500128_bib0065","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","article-title":"Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer","volume":"46","author":"M\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500128_bib0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40658-024-00682-8","article-title":"Quantitative SPECT imaging of 155Tb and 161Tb for preclinical theranostic radiopharmaceutical development","volume":"11","author":"Koniar","year":"2024","journal-title":"EJNMMI Phys."},{"key":"10.1016\/j.remnie.2025.500128_bib0075","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s11172-023-4022-8","article-title":"Preparation of 155Tb-labeled short somatostatin analog","volume":"72","author":"Moiseeva","year":"2023","journal-title":"Russ Chem Bull."},{"key":"10.1016\/j.remnie.2025.500128_bib0080","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2967\/jnumed.112.107540","article-title":"A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for \u03b1- and \u03b2-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative","volume":"53","author":"M\u00fcller","year":"2012","journal-title":"J Nucl Med."},{"issue":"S","key":"10.1016\/j.remnie.2025.500128_bib0085","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.nucmedbio.2013.11.002","article-title":"Future prospects for SPECT imaging using the radiolanthanide terbium-155 - production and preclinical evaluation in tumor-bearing mice","volume":"41","author":"M\u00fcller","year":"2014","journal-title":"Nucl Med Biol."},{"key":"10.1016\/j.remnie.2025.500128_bib0090","doi-asserted-by":"crossref","DOI":"10.1186\/s41181-021-00153-w","article-title":"Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging","volume":"6","author":"Favaretto","year":"2021","journal-title":"EJNMMI Radiopharm Chem."},{"key":"10.1016\/j.remnie.2025.500128_bib0095","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00259-013-2563-z","article-title":"Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate","volume":"41","author":"M\u00fcller","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500128_bib0100","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00259-014-2798-3","article-title":"Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model","volume":"41","author":"Gr\u00fcnberg","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500128_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41181-019-0063-6","article-title":"Production and characterization of no- carrier-added $^{161}$Tb as an alternative to the therapy","volume":"4","author":"Gracheva","year":"2019","journal-title":"EJNMMI Radiopharm Chem."},{"key":"10.1016\/j.remnie.2025.500128_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-016-0171-1","article-title":"Contribution of Auger\/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate","volume":"6","author":"Haller","year":"2016","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.remnie.2025.500128_bib0115","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3390\/cancers13092011","article-title":"Dosimetric analysis of the short-ranged particle emitter 161Tb for radionuclide therapy of metastatic prostate cancer","volume":"13","author":"Bernhardt","year":"2011","journal-title":"Cancers."},{"key":"10.1016\/j.remnie.2025.500128_bib0120","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2967\/jnumed.120.258376","article-title":"First-in-human application of terbium-161: a feasibility study using 161Tb-DOTATOC","volume":"62","author":"Baum","year":"2021","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2025.500128_bib0125","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.2967\/jnumed.124.267650","article-title":"Clinical trial protocol for VIOLET: a single-center, phase I\/II trial evaluation of radioligand treatment in patients with metastatic castration-resistant prostate cancer with [161Tb]Tb-PSMA-I&T","volume":"65","author":"Buteau","year":"2024","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2025.500128_bib0130","first-page":"1","article-title":"Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives","volume":"9","author":"Hooijman","year":"2024","journal-title":"EJNMMI Radiopharm Chem 2024 91."},{"key":"10.1016\/j.remnie.2025.500128_bib0135","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/1874471011666180416161908","article-title":"Development of 225 Ac Radiopharmaceuticals: TRIUMF perspectives and experiences","volume":"11","author":"Robertson","year":"2018","journal-title":"Curr Radiopharm."},{"key":"10.1016\/j.remnie.2025.500128_bib0140","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.apradiso.2004.06.013","article-title":"Cyclotron production of Ac-225 for targeted alpha therapy","volume":"62","author":"Apostolidis","year":"2005","journal-title":"Appl Radiat Isot."},{"key":"10.1016\/j.remnie.2025.500128_bib0145","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00259-021-05460-7","article-title":"Cyclotron production of 225Ac from an electroplated 226Ra target","volume":"49","author":"Nagatsu","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500128_bib0150","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jmir.2019.03.040","article-title":"High-purity actinium-225 production from radium-226 using a superconducting electron linac","volume":"50","author":"Grimm","year":"2019","journal-title":"J Med Imaging Radiat Sci."},{"key":"10.1016\/j.remnie.2025.500128_bib0155","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/ijnm.IJNM_115_18","article-title":"Alpha therapy with 225Actinium labeled prostate specific membrane antigen: reporting new photopeak of 78 kilo-electron volts for better image statistics","volume":"34","author":"Rasheed","year":"2019","journal-title":"Indian J Nucl Med."},{"key":"10.1016\/j.remnie.2025.500128_bib0160","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1088\/0031-9155\/57\/3\/771","article-title":"The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides","volume":"57","author":"Ackerman","year":"2012","journal-title":"Phys Med Biol."},{"key":"10.1016\/j.remnie.2025.500128_bib0165","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","article-title":"Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225 Ac-PSMA-617: dosimetry estimate and empiric dose finding","volume":"58","author":"Kratochwil","year":"2017","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2025.500128_bib0170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/pharmaceutics13010049","article-title":"Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications","volume":"13","author":"Nelson","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.remnie.2025.500128_bib0175","first-page":"1488","article-title":"Synthesis and evaluation of 99mTc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region","volume":"24","author":"Mohtavinejad","year":"2021","journal-title":"Iran J Basic Med Sci."},{"key":"10.1016\/j.remnie.2025.500128_bib0180","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s12350-019-01752-6","article-title":"68Ga-DOTA chelate, a novel imaging agent for assessment of myocardial perfusion and infarction detection in a rodent model","volume":"27","author":"Autio","year":"2020","journal-title":"J Nucl Cardiol."},{"key":"10.1016\/j.remnie.2025.500128_bib0185","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1021\/jm990141f","article-title":"Improved in vivo stability of actinium-225 macrocyclic complexes","volume":"42","author":"Deal","year":"1999","journal-title":"J Med Chem."},{"key":"10.1016\/j.remnie.2025.500128_bib0190","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol."},{"key":"10.1016\/j.remnie.2025.500128_bib0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.remnie.2025.500128_bib0200","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.120.251017","article-title":"First clinical results for PSMA-Targeted \u03b1-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients","volume":"62","author":"Zacherl","year":"2021","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2025.500128_bib0205","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225 Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2025.500128_bib0210","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00259-021-05474-1","article-title":"Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity","volume":"49","author":"Kratochwil","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500128_bib0215","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500128_bib0220","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/pharmaceutics13050599","article-title":"Bismuth-213 for targeted radionuclide therapy: from atom to bedside","volume":"13","author":"Ahenkorah","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.remnie.2025.500128_bib0225","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/jlcr.3792","article-title":"Targeted alpha therapy with bismuth-213 and actinium-225: meeting future demand","volume":"62","author":"Bruchertseifer","year":"2019","journal-title":"J Labelled Comp Radiopharm."},{"key":"10.1016\/j.remnie.2025.500128_bib0230","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.semnuclmed.2020.02.003","article-title":"Supply and clinical application of actinium-225 and bismuth-213","volume":"50","author":"Morgenstern","year":"2020","journal-title":"Semin Nucl Med."},{"key":"10.1016\/j.remnie.2025.500128_bib0235","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2015.00076","article-title":"Single-dose anti-CD138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model","volume":"2","author":"Fichou","year":"2015","journal-title":"Front Med."},{"key":"10.1016\/j.remnie.2025.500128_bib0240","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1021\/acs.molpharmaceut.0c00580","article-title":"Therapeutic efficacy of 213 Bi-labeled sdAbs in a preclinical model of ovarian cancer","volume":"17","author":"Dekempeneer","year":"2020","journal-title":"Mol Pharm."},{"key":"10.1016\/j.remnie.2025.500128_bib0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181473","article-title":"In vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy","volume":"12","author":"Chan","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.remnie.2025.500128_bib0250","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-10-0382","article-title":"Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia","volume":"16","author":"Rosenblat","year":"2010","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.remnie.2025.500128_bib0255","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","article-title":"213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience","volume":"41","author":"Kratochwil","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500128_bib0260","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00259-017-3657-9","article-title":"213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer","volume":"44","author":"Sathekge","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500128_bib0265","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s00259-018-4003-6","article-title":"Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study","volume":"45","author":"Autenrieth","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500128_bib0270","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s00259-018-4015-2","article-title":"Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue","volume":"45","author":"Krolicki","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500128_bib0275","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00259-018-4225-7","article-title":"Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma","volume":"46","author":"Kr\u00f3licki","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2025.500128_bib0280","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.4161\/cbt.4.12.2251","article-title":"Intralesional targeted alpha therapy for metastatic melanoma","volume":"4","author":"Allen","year":"2005","journal-title":"Cancer Biol Ther."},{"key":"10.1016\/j.remnie.2025.500128_bib0285","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4161\/cbt.6.6.4089","article-title":"Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma","volume":"6","author":"Raja","year":"2007","journal-title":"Cancer Biol Ther."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808925000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:57:04Z","timestamp":1758128224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808925000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2253808925000308"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500128","relation":{},"ISSN":["2253-8089"],"issn-type":[{"type":"print","value":"2253-8089"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State of the art and future perspectives of new radionuclides in Nuclear Medicine. Part II","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2025.500128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2025.500128","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular.","name":"copyright","label":"Copyright"}],"article-number":"500128"}}